2023
DOI: 10.1016/j.intimp.2022.109521
|View full text |Cite
|
Sign up to set email alerts
|

Galunisertib synergistically potentiates the doxorubicin-mediated antitumor effect and kickstarts the immune system against aggressive lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 7 publications
(1 citation statement)
references
References 44 publications
0
1
0
Order By: Relevance
“…PIIO-1 reversed the exhaustion of T cells and overcame primary resistance to anti-PD-1 ICIs was demonstrated in recent study [ 51 ]. In aggressive B-cell non-Hodgkin lymphoma, galunisertib (TGF- β RI inhibitor) in combination with the chemotherapeutic agent doxorubicin exerted synergistic anticancer effects through preventing CD8 + T cells exhaustion [ 52 ]. In head and neck cancer, reversing exhausted CD8 + T cells via neutralizing TGF- β was one of the ways to improve the efficacy of neoadjuvant immunotherapy [ 53 ].…”
Section: Tgf- β Is Involved In the Formation Of Cd...mentioning
confidence: 99%
“…PIIO-1 reversed the exhaustion of T cells and overcame primary resistance to anti-PD-1 ICIs was demonstrated in recent study [ 51 ]. In aggressive B-cell non-Hodgkin lymphoma, galunisertib (TGF- β RI inhibitor) in combination with the chemotherapeutic agent doxorubicin exerted synergistic anticancer effects through preventing CD8 + T cells exhaustion [ 52 ]. In head and neck cancer, reversing exhausted CD8 + T cells via neutralizing TGF- β was one of the ways to improve the efficacy of neoadjuvant immunotherapy [ 53 ].…”
Section: Tgf- β Is Involved In the Formation Of Cd...mentioning
confidence: 99%